Daily Sepsis Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Three standout studies advanced sepsis science today: a mechanistic paper reveals that high itaconate levels alkylate AIM2 to trigger macrophage PANoptosis; a multicountry genomic analysis shows that most neonatal Klebsiella pneumoniae sepsis cases in Africa and South Asia arise from nosocomial transmission; and a translational study links aspirin use to reduced sepsis-associated encephalopathy with supporting mechanistic signals.
Research Themes
- Immunometabolism-driven inflammatory cell death in sepsis
- Genomic epidemiology and nosocomial transmission of neonatal sepsis pathogens
- Drug repurposing and neuroprotection in sepsis-associated encephalopathy
Selected Articles
1. The alkylation of AIM2 by itaconate mediates macrophage PANoptosis during sepsis.
High itaconate levels covalently alkylate AIM2 at C113, stabilizing it to promote ASC oligomerization, PANoptosome assembly, and macrophage PANoptosis; the C113A mutation abrogates these effects. In vivo data confirm this itaconate–AIM2 axis exacerbates systemic sepsis, nominating AIM2 modification as a therapeutic target.
Impact: This is a first-in-kind mechanistic link between an immunometabolite and AIM2-driven PANoptosis in sepsis, revealing a druggable node. It reframes itaconate’s role from purely anti-inflammatory to context-dependent and pro-inflammatory at high levels.
Clinical Implications: While preclinical, targeting itaconate–AIM2 interactions or downstream PANoptosis offers a new therapeutic avenue to preserve macrophages and blunt hyperinflammation in severe sepsis.
Key Findings
- Itaconate covalently alkylates AIM2 at cysteine 113, stabilizing AIM2 and inducing conformational activation.
- AIM2 activation drives ASC oligomerization, PANoptosome assembly, and macrophage PANoptosis.
- The AIM2 C113A mutation abolishes itaconate-induced AIM2 stabilization and PANoptosis in vitro.
- In vivo models demonstrate that the itaconate–AIM2 axis contributes to systemic sepsis pathogenesis.
Methodological Strengths
- Multi-system validation including primary macrophages, cell lines, and in vivo sepsis models.
- Causality supported by site-directed mutagenesis (AIM2 C113A) and functional readouts of PANoptosis.
Limitations
- Translational relevance requires human validation; pathophysiological itaconate levels and cell-specific effects in patients are not defined.
- Therapeutic modulation feasibility (on-target selectivity and safety) remains untested.
Future Directions: Define itaconate levels and AIM2 modifications in human sepsis; evaluate pharmacologic inhibitors of AIM2 activation or PANoptosis; explore cell-type specificity and timing for intervention.
Although the immunometabolite itaconate has long been considered an anti-inflammatory, we found that its profound accumulation paradoxically drives macrophage cell death and pro-inflammatory responses. However, the exact molecular mechanisms underlying itaconate-induced macrophage toxicity remain unclear. Here, we demonstrate that pathophysiologically relevant high concentrations of itaconate covalently alkylate the absent in melanoma 2 (AIM2) protein at the cysteine 113 (C113) residue. Itaconate-mediated C113 alkylation structurally stabilizes the AIM2 protein and triggers a conformational change, enabling it to drive ASC oligomerization, PANoptosome assembly, and subsequent macrophage PANoptosis. Utilizing in vitro lentiviral reconstitution in primary macrophages alongside plasmid-mediated expression in cell lines, we rigorously confirmed that the AIM2 C113A mutation completely abolishes itaconate-induced AIM2 stabilization and PANoptosis. In vivo models further corroborated the pathogenic contribution of this axis to systemic sepsis. Taken together, our findings reveal a novel pro-inflammatory mechanism of itaconate via the post-translational modification of AIM2. The itaconate-AIM2 alkylation axis provides crucial mechanistic insights into macrophage depletion and systemic inflammation, highlighting a potential therapeutic target for severe sepsis.
2. Contribution of nosocomial transmission to Klebsiella pneumoniae neonatal sepsis in Africa and South Asia: An observational study of infection clusters inferred from pathogen genomics and temporal data.
Across 1,523 neonatal K. pneumoniae isolates from 27 units in 13 African and South Asian countries, 68% of infections fell within nosocomial transmission clusters; excluding index cases, at least 57.7% were acquired nosocomially. ESBL production was near-universal, and carbapenemase/ESBL gene carriage significantly associated with transmission; a limited set of MDR lineages drove most clusters.
Impact: This multicountry genomic study quantifies the dominant role of nosocomial transmission in neonatal sepsis by K. pneumoniae and pinpoints high-risk AMR lineages, directly informing infection prevention strategies.
Clinical Implications: Strengthening infection prevention and control (IPC), surveillance, and targeted interventions against MDR ESBL/carbapenemase lineages in neonatal units could markedly reduce neonatal sepsis burden.
Key Findings
- Of 1,523 isolates, 1,035 infections (68.0%) were within nosocomial transmission clusters; excluding index cases, at least 57.7% were nosocomial.
- A total of 156 clusters were inferred, with 83 clusters comprising ≥3 cases and sizes ranging from 2 to 188 neonates.
- ESBL producers accounted for 90.9% of isolates; 14 STs associated with transmission across multiple units drove approximately two-thirds of infections.
- Carbapenemase (aOR 2.08) and ESBL (aOR 2.48) gene carriage were significantly associated with transmission after adjusting for site.
Methodological Strengths
- Large, multicountry dataset with bacterial whole-genome sequencing and temporal linkage.
- Robust sensitivity analyses across genetic distance methods and temporal thresholds; site-adjusted regression for transmission associations.
Limitations
- Limited clinical and facility-level metadata precluded high-resolution transmission mapping and analysis of site-level determinants.
- Observational, retrospective aggregation may introduce selection biases across contributing studies.
Future Directions: Integrate clinical/facility data with genomics for actionable transmission mapping; implement and evaluate IPC bundles targeting high-risk STs; expand real-time sequencing surveillance.
BACKGROUND: Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial resistant (AMR) infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of K. pneumoniae neonatal sepsis attributable to nosocomial transmission in African and South Asian countries. METHODS AND FINDINGS: We estimated the proportion of invasive K. pneumoniae disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 K. pneumoniae isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units, and these were collectively responsible for two-thirds of all infections. Carriage of carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04, 4.14]; p = 0.04) and ESBL genes (aOR = 2.48 [95% CI: 1.26, 4.90]; p = 0.006) were significantly positively associated with transmission in a logistic regression model with site as a covariate. Limitations of this study include the lack of sufficient clinical data to allow high-resolution investigation of transmission dynamics and lack of facility-level data to investigate contributors to the observed differences in transmission burden across sites. CONCLUSIONS: Nosocomial transmission contributes to a substantial proportion of K. pneumoniae sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with the same drug-resistant lineages that are recognised as high-risk clones associated with hospital outbreaks in high-income countries, indicating global connectivity of the AMR pathogen population.
3. Aspirin mitigates sepsis-associated encephalopathy by modulating ICAM-1 and MMP-9 signaling: Evidence from clinical cohorts and mechanistic experiments.
Analyses of MIMIC-IV and eICU cohorts using PSM and IPTW show aspirin use associates with lower SAE incidence without excess GI bleeding; meta-analysis supports a protective association (OR 0.69). Complementary mechanistic data implicate ICAM-1/MMP-9 modulation as a neuroprotective pathway.
Impact: This study bridges clinical epidemiology with mechanistic biology to support low-cost aspirin as a plausible preventive strategy for SAE, a major unmet need in sepsis care.
Clinical Implications: While RCTs are needed, clinicians may consider aspirin’s risk–benefit profile in select septic patients at high SAE risk and low bleeding risk, and monitor ICAM-1/MMP-9-linked biomarkers in future trials.
Key Findings
- Aspirin use was associated with reduced incidence of SAE in ICU septic patients using PSM and IPTW on MIMIC-IV and eICU databases.
- No increase in gastrointestinal bleeding was observed among aspirin users in the analyzed cohorts.
- Meta-analysis showed a pooled protective association for aspirin against SAE (OR 0.69, 95% CI 0.57–0.83).
- Mechanistic experiments implicate modulation of ICAM-1 and MMP-9 signaling as a pathway for aspirin’s neuroprotection.
Methodological Strengths
- Use of two large, independent ICU databases with propensity score matching and IPTW to mitigate confounding.
- Translational integration of mechanistic experiments with clinical cohort findings.
Limitations
- Observational design cannot eliminate residual confounding; dosing, timing, and indications for aspirin may bias associations.
- Safety endpoints beyond GI bleeding and long-term neurocognitive outcomes were not detailed; RCT confirmation is needed.
Future Directions: Conduct randomized trials testing aspirin for SAE prevention with stratification by bleeding risk and mechanistic biomarker panels (ICAM-1/MMP-9); define optimal dose/timing.
Sepsis-associated encephalopathy (SAE) is a devastating complication contributing substantially to intensive care unit mortality and long-term cognitive impairment. Although observational studies suggest that aspirin use was associated with reduced sepsis-related mortality, its neuroprotective potential against SAE and underlying molecular mechanisms remain unclear. Using data from the Medical Information Mart for Intensive Care IV and eICU Collaborative Research Database, we demonstrated through propensity score matching and inverse probability of treatment weighting that aspirin use was significantly associated with reduced SAE incidence without increased gastrointestinal bleeding risk. Meta-analysis yielded a pooled protective association (OR 0.69, 95% CI 0.57-0.83) with moderate heterogeneity (I